/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Our Mission To change the non-transparent $5.3 trillion 1 healthcare industry with innovation that removes friction and complexities with vertical integration, process simplification, automation, and digitalization. Overview Health in Tech ( HIT ) is an AI-enabled insurance technology platform company, which offers a marketplace that improves processes in the healthcare industry through vertica…
$0.97
+$0.01 (+0.83%)
EOD Sep 1, 2026
17.48% operating margin is respectable but not wide. ROIC at 34.73%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 69.9%, still solid. Margins contracted 4.1pp, which offsets some of the top-line progress.
ROIC dropped from 36.75% to 34.73%, capital efficiency is deteriorating. Operating margin contracted 4.1pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$32M
▲ +69.9% YoY
Net Income (TTM)
-$4M
▲ +90.7% YoY
Op. Margin
3.42%
▼ -4.1pp YoY
ROIC
4.58%
▼ -2.0pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$5M
▲ +44.0% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$7M
Continue Research
SourceComputed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Health In Tech (HIT)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Health In Tech scores 25/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Health In Tech scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 3.4% operating margin and a 4.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh HIT's valuation and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.